• September 2 (THU)
  • September 3 (FRI)
Time Room A Room B Room C Room D
8:40-9:00 Opening Ceremony Oral / Poster
09:00-10:30 ASCO/KSMO
Joint Symposium 1

Integrating next-generation sequencing into clinical practices: Sharing the real-world experiences
Scientific Symposium 1
Immunotherapy beyond anti-PD1/PDL1 antibody
Scientific Symposium 2
Resistance mechanism of immunotherapy
Satellite Symposium 1
pfizer From science to Real-world data(RWD) with breast cancer patient
Satellite Symposium 2
pfizer Management of mPaCa patients : Focused on Liposomal Irinotecan(ONIVYDE)
10:30-10:50 Break (20 min.)
10:50-11:30 Plenary Lecture 1
Checkpoint blockade therapy for melanoma: Combinations to improve outcomes
11:30-12:10 Luncheon Symposium 1
MSD Front-line therapy for advanced NSCLC immunotherapy and immunotherapy combinations
Luncheon Symposium 2
ONO Pharma Korea / BMS Korea Changing the treatment landscape for gastric and GEJ cancer: Nivolumab plus chemotherapy
Luncheon Symposium 3
Boryung First bevacizumab biosimilar in Korea, ONBEVZI
12:10-12:40 Break (30 min.)
12:40-14:10 Scientific Symposium 3
Clinical application of ctDNA profile
Scientific Symposium 4
Targeting endocrine pathway: Breast & prostate
Satellite Symposium 3
MSD The Welcome rain, Pembrolizumab: New hope for MSI-H/dMMR colorectal cancer patients
Collaborative Symposium 1
Moving forward to a new paradigm of treatment in advanced gastric cancer
Satellite Symposium 4
Eisai The evolving HCC treatment landscape: What is the role of LENVIMA
Satellite Symposium 5
Jeil TAS-102, New therapeutic option for patients with CRC / GC
14:10-14:30 Break (20 min.)
14:30-15:30 Scientific Symposium 5
Recent advances in stomach cancer & GIST
Oncology Multi-Disciplinary Symposium KOR
Multidisciplinary approach for patients with brain metastasis
Joint Symposium

Conducting phase I clinical trial with targeted therapy/immunotherapy
Oral Discussion 1
Breast cancer / Head&Neck cancer
15:30-15:50 Break (20 min.)
15:50-17:20 JSMO/KSMO
Joint Symposium

Biomarker driven clinical trials : Sharing experiences
Joint Symposium

Updates of IO treatments and Asian subgroup analysis in oncology clinical trials
Scientific Symposium 6
Recent advances in NSCLC & SCLC
Satellite Symposium 6
Ipesen Shifting perception in treatment of advanced renal cell carcinoma
Satellite Symposium 7
Novartis Evolving treatment landscape with CDK 4/6 inhibitors in metastatic breast cancer
17:20-18:00 Plenary Lecture 2
Cancer clinical trials and cancer patients care during or after COVID-pandemic
Giuseppe Curigliano (Italy)
Time Room A Room B Room C Room D
09:00-09:40 Plenary Lecture 3
Non-genetic cancer therapy resistance: A cell biologist's perspective
Joan S Brugge (USA)
Oral / Poster
09:40-10:00 Break (20 min.)
10:00-11:30 ASCO/KSMO
Joint Symposium 2

Ladder of cancer treatment: Precision medicine and palliative care
Joint Symposium

De-escalation/escalation of radiotherapy
Special Symposium 1
A new path to cardiotoxicity management in the age of precision medicine
Satellite Symposium 8
takeda The evolving ALK+ NSCLC paradigm: The future of 1st line and beyond
Satellite Symposium 9
MSD KEYTRUDA® for 1L TNBC – A new hope that blooms in the wild land
11:30-12:10 Luncheon Symposium 4
Roche Tecentriq + Avastin : Reigniting progress in the HCC treatment landscape
Luncheon Symposium 5
Astrazeneca Paradigm-changing treatment strategy for lung cancer covering early to advanced stages
Collaborative Symposium 2
The development of RAS/RAF targeted drugs
12:10-12:40 Break (30 min.)
12:40-14:00 Scientific Symposium 7
Recent advances in Hepatocellular carcinoma/Pancreas-Biliary Ca
Scientific Symposium 9
Expanding indications of PARP inhibitors
Multidisciplinary Oncology Team Education Session 1 KOR
Advances in toxicity management
Satellite Symposium 10
innoN Optimal treatment strategy in metastatic colorectal cancer
Satellite Symposium 11
Yuhan From clinical trials to practice: New era of EGFRm NSCLC treatment, LECLAZA®
14:00-14:20 Break (20 min.)
14:20-15:50 KSSO/KSMO
Joint Symposium

Multimodality treatment strategy: Primary breast surgery in stage IV breast cancer; Neoadjuvant chemotherapy followed by surgery in locally advanced pancreatic cancer
Joint Symposium

Tumor microenvironment and pathology
Multidisciplinary Oncology Team Education Session 2 KOR
Current strategies for maximizing the benefit of immunotherapy
Satellite Symposium 12
Sanofi What is being considered for treatment decision for 2nd line mCRC?
Satellite Symposium 13
Amgen Optimal bone health management with BTA in bone metastatic solid tumor
15:50-16:00 Break (10 min.)
16:00-17:00 Scientific Symposium 8
Infection and cancer: HBV, HIV, HPV, CMV etc
Joint Symposium

State-of-the-art oncologic imaging analysis
Multidisciplinary Oncology Team Education Session 3 KOR
Targeted therapy : Clinical effects and resistance
Oral Discussion 2
Hepato-biliary-pancreatic cancer/GI cancer/Lung cancer
17:00-17:40 Plenary Lecture 4
Drug development: The revolution of the last 15 years
Jean-Charles SORIA (USA)
17:40-18:00 Closing Ceremony & Awards